29-Apr-2024
Benzinga (Mon, 29-Apr 1:04 PM ET)
FLGC, BTOG and CAUD among mid-day movers
Seeking Alpha News (Mon, 29-Apr 12:31 PM ET)
Phibro Animal Health Expands Portfolio with Zoetis Acquisition
TipRanks (Mon, 29-Apr 6:22 AM ET)
Zoetis to sell medicated feed additive portfolio to Phibro Animal Health for $350M
Seeking Alpha News (Mon, 29-Apr 4:51 AM ET)
Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health
Business Wire (Sun, 28-Apr 6:30 PM ET)
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
Business Wire (Thu, 18-Apr 4:00 PM ET)
Phibro Animal Health Corporation to Participate in Barclays Global Healthcare Conference
Business Wire (Thu, 29-Feb 4:00 PM ET)
Phibro Animal Health Corporation to Participate in Bank of America 2024 Animal Health Summit
Business Wire (Wed, 14-Feb 4:00 PM ET)
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
Business Wire (Wed, 7-Feb 4:30 PM ET)
Phibro Animal Health Corporation Declares Quarterly Dividend
Business Wire (Tue, 6-Feb 4:15 PM ET)
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Phibro Animal Health - Class A trades on the NASDAQ stock market under the symbol PAHC.
As of April 29, 2024, PAHC stock price climbed to $16.78 with 728,030 million shares trading.
PAHC has a beta of 0.69, meaning it tends to be less sensitive to market movements. PAHC has a correlation of 0.03 to the broad based SPY ETF.
PAHC has a market cap of $679.65 million. This is considered a Small Cap stock.
Last quarter Phibro Animal Health - Class A reported $250 million in Revenue and $.33 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.05.
In the last 3 years, PAHC stock traded as high as $31.00 and as low as $9.40.
The top ETF exchange traded funds that PAHC belongs to (by Net Assets): IJR, VTI, IWM, VXF, IJS.
PAHC stock has underperformed the market in the last year with a return of +12.4%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PAHC shares. However, PAHC has outperformed the market in the last 3 month and 2 week periods, returning +44.9% and +28.0%, while SPY returned +5.0% and -0.2%, respectively. This indicates PAHC has been having a stronger performance recently.
PAHC support price is $12.38 and resistance is $13.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PAHC stock will trade within this expected range on the day.